Revolution Medicines FDA Breakthrough Therapy for daraxonrasib, ups cost guidance

 

Revolution Medicines posts fiscal Q2 2026 loss with non-GAAP EPS -3.06, $0 revenue, wins FDA Breakthrough Therapy for daraxonrasib

• Non-GAAP EPS of -3.06 declined 134% year over year, significantly worsening from prior-year quarter.
• Quarterly results missed both EPS and revenue estimates, with revenue reported at $0 for fiscal Q2 2026.
• Company raised GAAP operating expense guidance, updating outlook for operating costs for the current fiscal period.
• FDA Breakthrough Therapy designation granted for daraxonrasib in previously treated KRAS-mutant NSCLC.

https://finviz.com/stock?t=RVMD&p=d